• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
COPD. Author manuscript; available in PMC Feb 1, 2011.
Published in final edited form as:
PMCID: PMC2924193

Genetic Epidemiology of COPD (COPDGene) Study Design

Elizabeth A. Regan, MD, PhD,1 John E. Hokanson, PhD,2 James R. Murphy, PhD,1 Barry Make, MD,1 David A. Lynch, MD,1 Terri H. Beaty, PhD,3 Douglas Curran-Everett, PhD,1,2 Edwin K. Silverman, MD, PhD,4 and James D. Crapo, MD1, for the COPDGene Investigators



COPDGeneis a multicenter observational study designed to identify genetic factors associated with COPD. It will also characterize chest CT phenotypes in COPD subjects, including assessment of emphysema, gas trapping, and airway wall thickening. Finally, subtypes of COPD based on these phenotypes will be used in a comprehensive genome-wide study to identify COPD susceptibility genes.


COPDGene will enroll 10,000 smokers with and without COPD across the GOLD stages. Both Non-Hispanic white and African-American subjects are included in the cohort. Inspiratory and expiratory chest CT scans will be obtained on all participants. In addition to the cross-sectional enrollment process, these subjects will be followed regularly for longitudinal studies. A genome-wide association study (GWAS) will be done on an initial group of 4000 subjects to identify genetic variants associated with case-control status and several quantitative phenotypes related to COPD. The initial findings will be verified in an additional 2000 COPD cases and 2000 smoking control subjects, and further validation association studies will be carried out.


COPDGene will provide important new information about genetic factors in COPD, and will characterize the disease process using high resolution CT scans. Understanding genetic factors and CT phenotypes that define COPD will potentially permit earlier diagnosis of this disease and may lead to the development of treatments to modify progression.


Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the United States and an important public health problem 1. An estimated 24 million individuals in the U.S. may be affected by COPD 2. Both the number of affected individuals and the number of deaths from COPD are expected to increase as the population ages 3. COPD is a heterogeneous condition, with a variety of disease-related phenotypes 4,5. Better understanding of the disease mechanisms is needed to develop effective treatments and prevention strategies. To accomplish this, we need improved understanding of the etiology of COPD, clinical classifications of the disease that are biologically and medically coherent, and knowledge of genetic factors that influence risk of COPD.

COPD is strongly associated with smoking, but not all smokers will develop COPD, suggesting that there may be unique genetic differences among individuals leading to greater susceptibility to the most adverse effects of cigarette smoke in some individuals 6. Relatives of COPD patients show an increased prevalence of airflow obstruction, which supports a role for genetic factors predisposing smokers to COPD 79. Smokers with first degree relatives affected by COPD have two to three times the risk of developing disease 9;10. Genetic factors have been associated with response to lung volume reduction surgery 11 as well as specific patterns of emphysema 12 and degree of functional impairment 13. Estimated heritability for decline in lung function with age using parent-offspring pairs who both smoke are 0.18 for FEV1 and 0.39 for FVC 14. Because COPD is likely the result of multiple genes, some of which may interact with environment risk factors (primarily smoking), estimates of heritability that do not include the effects of smoking on lung function are likely to underestimate the true genetic component in COPD.

The Genetic Epidemiology of COPD (COPDGene) Study was designed to identify genetic factors in COPD, to define and characterize disease-related phenotypes, and to assess the association of disease-related phenotypes with the identified susceptibility genes. This multi-center study is funded by the National Heart, Lung and Blood Institute (NHLBI). A key feature of the project is to enroll a large cohort (10,000) of subjects, spanning the breadth of disease severity including smokers and non-smokers without COPD as controls. Two groups are being studied: Non-Hispanic Whites and Non-Hispanic African Americans.


Study Design

10,000 subjects are planned to be enrolled with 2/3 non-Hispanic White and 1/3 African American, distributed across the full spectrum of disease severity and both genders. The cohort is specifically being recruited for a genome-wide association study (GWAS) analysis and is large enough to provide adequate statistical power to detect genetic variants exerting modest effects on risk. COPD subtypes will be defined based on the presence and severity of parenchymal and airway disease on inspiratory and expiratory high-resolution chest CT scans. The Genome-Wide Association Study (GWAS) was designed to involve four phases. There will be an initial GWAS on a balanced group of 4000 subjects of current or former smoker case and control subjects (2600 White and 1400 African American) in Phase 1. Statistical signals (SNPs in or between genes) identified in Phase I will be confirmed in Phase II with a custom SNP array using the remaining 2000 cases and 2000 controls in the cohort. In Phase III SNPs in genes/regions identified and confirmed in Phases I and II will be investigated with regional fine mapping and tests of associations to identify causal genes. The final group of candidate genes will be replicated in other COPD cohorts as Phase IV. With continued improvements in SNP genotyping technology additional phases (beyond Phase 1) may be analyzed at the genome-wide level.

The COPDGene cohort is also established for longitudinal follow-up with regular contacts made to determine mortality, comorbid disease events and disease status. Renewed funding will be sought to re-assess the subjects with spirometry, clinical evaluation and repeat chest CT to accumulate information about progression of the disease.


Twenty one clinical study centers (see investigator list above) throughout the United States are enrolling participants. Each study site has obtained local IRB approval to enroll participants in this project and all subjects provide informed consent to participate in the study.

Inclusion and Exclusion Criteria

The primary inclusion criteria are self – identified racial/ethnic category as either non-Hispanic whites or African-Americans between ages of 45 and 80 years with a minimum of 10 pack-year smoking history (except non-smoking controls). Pregnant women are excluded because CT scans are part of the study protocol and represent an unacceptable risk to a fetus. Other exclusion criteria are a history of other lung disease except asthma (e.g. pulmonary fibrosis, extensive bronchiectasis, cystic fibrosis), previous surgical excision of at least one lung lobe (or lung volume reduction procedure), active cancer under treatment, suspected lung cancer (large or highly suspicious lung mass), metal in the chest, recent exacerbation of COPD treated with antibiotics or steroids, recent eye surgery, MI, other cardiac hospitalization, recent chest or abdominal surgery, inability to use albuterol, multiple self-described racial categories, history of chest radiation therapy, and first or second degree relative already enrolled in the study. Subjects with recent COPD exacerbations can be enrolled one month after their exacerbation.

Smokers who have an unclassified pattern by GOLD criteria on spirometry, denoted as GOLD U (normal FEV1/FVC but reduced FEV1) are eligible for the study but will be analyzed separately. Since a key goal of this project is to define COPD phenotypes in the most complete manner possible, this group of participants was retained to allow the full breadth of smoking-related lung disease to be studied.

Individuals diagnosed with asthma, in either the COPD or smoking control groups, are included in COPDGene. COPD subjects are often diagnosed with asthma, and therefore excluding asthmatics would not provide an accurate distribution of COPD subjects. In order to include the full spectrum of COPD subjects, potential participants will not be excluded based on spirometric bronchodilator responsiveness. Both case and control groups will be monitored throughout the study for numbers of asthmatics (as defined by report of physician diagnosis of asthma) in each group and data analysis both with and without asthmatics will assess the impact of the asthma phenotype on inferences from our genetic analyses.


CT scans are acquired using multi-detector CT scanners (at least 16 detector channels). Volumetric CT acquisitions are obtained both on full inspiration (200mAs), and at the end of normal expiration (50 mAs). Image reconstruction utilizes sub-millimeter slice thickness, with smooth and edge-enhancing algorithms. Detailed CT protocols are provided in Appendix 1.

Data Collection

Each study subject has pre- and post-bronchodilator spirometry performed using a standardized protocol and spirometer (ndd EasyOne Spirometer, Zurich, Switzerland). Information collected from each subject includes a modified American Thoracic Society (ATS) Respiratory Epidemiology Questionnaire, demographic information, medications, medical history, and St George’s Respiratory Questionnaire (SGRQ) (see full data collection forms on COPDGene web site at www.COPDGene.org). Height, weight, blood pressure and oxygen saturation (on room air) are also assessed. A standardized six minute walk test is performed on each subject. Inspiratory and expiratory CT scans are done. A blood sample for DNA is obtained from each subject; serum and plasma are stored for future biomarker studies at the COPDGene Biorepository at John Hopkins University.


Recruitment of adequate numbers of subjects distributed between controls and four COPD GOLD stages is a key factor for success. Recruitment by age, gender, race, and disease status for each clinical study center is monitored on a real-time basis by the Data Coordinating Center (DCC). A Certificate of Confidentiality from the US Department of Health and Human Services was obtained at the onset of the study to provide additional protection for the research participants and their subsequently generated data on genetic markers.

Data Management

All study data are ultimately stored in the COPDGene Data Coordinating Core (DCC) at the Division of Biostatistics and Bioinformatics at National Jewish Health. Data are entered by each site through a web-accessible system. Verification of eligibility is completed via a website questionnaire after subjects sign the research consent form, and subjects are tracked for completion of all study data. If a participant is excluded or discontinues during or after the study procedures, the specific exclusion or discontinuation reason is recorded in the database.

Pulmonary Function Test (PFT) Core

All spirometry data are collected using the ndd EasyOne Spirometer (Zurich, Switzerland). It is an ultrasound-based spirometer utilizing a dual beam Doppler approach to flow measurement and has Windows-based software program to collect, calculate and store final spirometry data. All spirometry studies are reviewed centrally by the PFT QA Core to insure quality control (see below).

Imaging Core

The Imaging Core is centered at National Jewish and works on a collaborative basis with the Iowa Comprehensive Lung Imaging Center at the University of Iowa and imaging staff at the Brigham and Women’s Hospital. Research assistants log receipt of images, perform quality control analysis, coordinate required readings, and assist with quantitative analysis. De-identified images are submitted on DVDs to the Image Core in DICOM format, using a study ID as the only identifier.

Sample Storage Core

The Sample Storage Core at Johns Hopkins University coordinates blood sample shipments and storage using barcode labels and the Freezerworks database to track samples through intake and processing to serum, plasma, and DNA. It also provides an inventory of the complete sample storage for the project. Each subject has a minimum of 50 micrograms of DNA stored along with additional aliquots of stored buffy coat, plasma and serum.

Training of Study Centers

An initial training program was developed to insure constant data quality across the clinical study centers. There were six major areas identified for training: spirometry, subject data collection and data entry, participant eligibility, safety assessment and functional tests, chest CT scans and blood/DNA collection and shipping. In addition to in-person training for coordinators at the Study Launch Meeting, training programs were made available on the study website for each site to train new coordinators. Spirometry skills were assessed after the formal training by requiring each coordinator to submit test values and flow curves on 3 naïve subjects. Radiology technicians were trained at their local sites by a web-based program describing CT scan methods, to provide uniformity in verbal instructions to subjects, performance of the CT protocol, and management of CT data.

Each Clinical Center was individually assessed for completion of all training activities. After obtaining final IRB approval for the project, the Clinical Center director and coordinator(s) participated in a teleconference with the administrative core to initiate activation of the Clinical Center. Two pilot subjects were enrolled at each site and subject data collection, data transfer, CT methods and shipping procedures were reviewed and approved prior to beginning full enrollment.

Quality control

Each of the study Cores (PFT, Imaging, Biorepository, Genome-Wide Analysis, Candidate Genotyping, and the DCC) developed plans for quality control of data handling. The DCC is the central storage site for all study data and leads the QA program for data entry, including range-checking of data on entry, multi-variable validation and monthly reports on data quality, and maintenance of an auditing record of all data changes. Each study center is informed weekly about out-of-range data so problems can be resolved rapidly. Data identified as out of range are reviewed by the Quality Control Committee and when necessary by the Adjudication Committee.

CT scan quality control

Quality assurance of CT images is multi-level. Each CT scan is visually inspected by the local clinical radiologist for adequate inspiration, absence of motion artifact, and inclusion of all parts of the chest. At the Imaging Core, a trained Professional Research Assistant evaluates the scan for technical completeness, compliance with protocol, adequacy of inspiration, and presence of motion artifact. The quality of the automated segmentations of airways is verified. Finally, the stability of CT measurements for each scanner used in the study is monitored by monthly scanning using a custom COPDGene phantom designed for this study.

Spirometry quality control

All spirometry data are collected using the ndd EasyOne Spirometer (Zurich, Switzerland). Each spirometer is tested against the ATS 24 and 26 standard waveforms and certified that it meets the ATS requirements, and each system will be continuously standardized with a 3.0 liter syringe located at each site. Each clinical coordinator was certified by the PFT Core after spirometry training. The PFT data is uploaded daily to the PFT QA Center’s FTP site, and the PFT Core feeds the data directly into a quality assessment software package. Quality assessments are made on each study. Studies that fail the quality assessment are reviewed by the PFT QC committee to be deleted or accepted for the study data set.


In the GWAS analysis the primary association will be COPD status defined as GOLD Stages 2–4 in smokers with controls being smokers with normal spirometry (post-bronchodilator FEV1/FVC > 0.7 and FEV1 > 80% predicted). Other outcome measures for genetic association will be post-bronchodilator FEV1 – used as a continuous variable in COPD cases, emphysema (% of lung <−950 HU – used as a continuous variable in COPD cases), air trapping on expiratory CT (% of lung < −856 HU – used as a continuous variable in COPD cases) and airway disease as a continuous variable (wall area percent of the 4th and 5th generation airways).

CT phenotyping

The following analyses are performed on segmented lung images, using VIDA software (VIDA Diagnostics, http://www.vidadiagnostics.com): total inspiratory and expiratory lung volumes, mean lung attenuation, and relative lung volumes (for the whole lung, and for each lobe) falling below attenuation thresholds of −950, −910 and −856 HU. Emphysema distribution is assessed by comparing percent emphysema in central vs. peripheral lung and upper vs. lower lobes. Automated airway segmentation and quantification are performed, as discussed by Hoffman et al 15. For each bronchial tree, multiple parameters are calculated for third, fourth, fifth, and sixth generation bronchi, including wall area, lumen area, wall thickness, and luminal diameter. Parallel imaging analyses of percent emphysema and percent gas trapping are also being done using 3D Slicer (http://www.slicer.org/).

Genetic analysis plan

COPDGene will apply three general analytical strategies for the genome-wide SNP data to both maximize statistical power in identifying disease susceptibility loci (DSL) and minimize false positive results. 1. Immediate identification of DSL achieving genome-wide significance (using methods for screening and testing in the same dataset 16), 2. Ranking SNPs based on estimated effect size for 2-Stage design, and 3. Combining results across racial groups through either meta-analytic techniques or by incorporating covariates that summarize genetic background.

Genetic association tests will be performed for both qualitative and quantitative COPD-related phenotypes. Separate association analysis will be performed in the GOLD Stage 1 subjects and GOLD-U subjects to see if these subsets have significantly different distributions of disease-associated alleles and/or haplotypes compared to those seen in other GOLD Stage subjects. Power to detect significant associations with COPD for specific candidate gene SNPs was determined for the approximate case-control samples of African Americans (1500 cases/1500 controls) and non-Hispanic whites (3000 cases/3000 controls) after adjusting for multiple comparisons. Power to detect a significant association was 99% for OR ≥1.5 with allele frequency >0.1 (NHW), and for OR ≥1.75 with allele frequency ≥0.1 (AA).

Data Sharing

The resources and the results of the COPDGene study will be made available to other investigators in a manner that will allow the broad scientific community to benefit from the work of this project while protecting the privacy and confidentiality of research subjects. The data sharing plan is to provide all datasets (including genotype and phenotype data) to dbGAP (http://www.ncbi.nlm.nih.gov/sites/entrez/dbgap) as soon as possible after the data is verified to the standards described in the QC section above.


We anticipate that COPDGene will generate a unique, large cohort of well-phenotyped subjects for COPD research. The high level of phenotypic characterization will provide a valuable resource for studies into the genetics, epidemiology, and natural history of COPD. Two recent genome-wide studies of COPD have identified SNPs in proximity to the hedgehog-interacting protein (HHIP) 17;18. The study by Wilk et al was general population-based, and their association of HHIP was to FEV1/FVC rather than to COPD specifically. Pillai et al in addition to the association with HHIP also found two SNPs in a genomic region containing the α-nicotinic acetylcholine receptor (CHRNA 3/5) that associated strongly with COPD in a case-control design, and associated with lung function as well. These valuable studies do not exclude the need for further GWAS studies in COPD. COPDGene has several strengths for future work including: a larger sample size, a substantial African American population and plans to perform replication studies on a larger number of SNPs than Pillai et al.

The relative importance of common vs. rare variants in the etiology of complex diseases remains a subject of some debate. Common genetic variants are likely to contribute to the control of complex diseases, although their individual effects on risk may be quite modest, and furthermore multiple genes are likely to be involved. Rare genetic variants are also likely to contribute to risk, and while their individual effect may be larger, their rarity in the population makes it difficult to identify and confirm their effects in case-control designs. Identification of very rare genetic variants is not practical using genetic association analysis because of the extremely large sample sizes needed; however, the sample sizes proposed in this project will enable us to identify relatively rare alleles (e.g., allele frequency as low as 0.05) associated with moderately increased disease risk. A major limitation of GWA analysis in a single phase is the unacceptable number of false positive SNPs that will be identified simply due to the extremely large number of statistical tests conducted. The multi-phase study design proposed will specifically to limit false positive findings, while maximizing the number of true positives. Furthermore, we will compare tests within the COPDGene cohort to results from other cohorts and family-based studies to replicate our results.

In addition to the analyses of the entire COPDGene population listed above, separate analyses of the GOLD Stage 1 cases will be performed. We will attempt to identify a normal subgroup and an early disease subgroup within this phenotypic category based on their CT emphysema, CT airway, and spirometric characteristics. The relationship of this “normal” subset to functional impairment and disease impact measures will be assessed. We hypothesize that individuals in the putative normal subgroup will have less functional impairment, less evidence for disease impact, and fewer exacerbations. Ultimately, longitudinal follow-up will be required to determine if the hypothesized “normal” subgroup of GOLD 1 subjects are less likely to progress to full airflow obstruction. However, cross-sectional analysis of GOLD 1 subjects will determine whether clinical heterogeneity can be discerned within these groups using CT data.

There are several future research opportunities generated by this study that will be important for the general pulmonary research community. First, additional characterization of functional variants in any and all susceptibility genes identified here will be required. This will involve resequencing these genes to identify specific mutations followed by further biochemical or physiological studies to define the functional impact of these variants using animal models. Second, longitudinal investigation of all cases and controls recruited for COPDGene will provide new insights into the natural history, epidemiology and the genetic basis of COPD. This would include improved understanding of the GOLD 1 and GOLD U groups, plus assessment of risk factors for COPD progression, morbidity, and mortality.


COPD is a disease with important public health implications given its often profound effects on functional capacity, quality of life and mortality. At this time there is a dearth of effective disease treatments for moderate to severe disease or effective secondary prevention strategies for early or occult disease. Further progress in these areas is hampered by the long latency period between smoking exposure and development of clinical disease, as well as by a relatively small proportion of smokers who develop symptomatic disease. Wide variation in disease expression patterns (airway disease, emphysema, extrapulmonary effects and patterns of exacerbations) may limit statistical power to detect successful results within these subsets in therapeutic trials.

COPDGene with its large population and focus on CT phenotypes proposes to define subsets of COPD that may reflect effects of specific genetic variants. Careful CT phenotyping may generate diagnostic imaging biomarkers and permit early disease identification in high risk groups. This early diagnosis of asymptomatic disease will provide new opportunities to develop prevention strategies and treatment to limit disease progression. Available treatments will also spur new efforts to encourage screening for early disease in smokers with continued emphasis on smoking cessation. The genetic associations expected from performing GWAS in this large cohort may reveal novel directions for defining disease mechanisms while advancing knowledge about basic mechanisms and also providing opportunities for treatment and prevention.

Finally, the wealth of data to be accrued in COPDGene will be stored and made available to the broader scientific community for future studies. This will include the detailed phenotypic subject information, whole genome data and the imaging data from CT scans.

Supplementary Material



This work is also supported by the Monfort Family Foundation and by the COPD Foundation. AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals Corporation, and Sepracor Inc are ongoing supporters of the project through the COPDGene Industry Advisory Group.

Funding: The project described is being supported by Award Numbers U01HL089897 and U01HL089856 from the National Heart, Lung, And Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, And Blood Institute or the National Institutes of Health.

COPDGene Investigators

Ann Arbor VA: Jeffrey Curtis, MD (PI), Ella Kazerooni, MD (RAD)

Baylor College of Medicine, Houston, TX: Nicola Hanania, MD, MS (PI), Philip Alapat, MD, Venkata Bandi, MD, Kalpalatha Guntupalli, MD, Elizabeth Guy, MD, William Lunn, MD, Antara Mallampalli, MD, Charles Trinh, MD (RAD), Mustafa Atik, MD

Brigham and Women’s Hospital, Boston, MA: Dawn DeMeo, MD (Co-PI), Craig Hersh, MD (Co-PI), Francine Jacobson, MD, MPH (RAD)

Columbia University, New York, NY: R. Graham Barr, MD, DrPH (PI), Byron Thomashow, MD, John Austin, MD (RAD)

Duke University Medical Center, Durham, NC: Neil MacIntyre, Jr., MD (PI), Lacey Washington, MD (RAD), H Page McAdams, MD

Fallon Clinic, Worcester, MA: Richard Rosiello, MD (PI), Timothy Bresnahan, MD

Health Partners Research Foundation, Minneapolis, MN: Charlene McEvoy, MD, MPH (PI), Joseph Tashjian, MD (RAD)

Johns Hopkins University, Baltimore, MD: Robert Wise, MD (PI), Nadia Hansel, MD, MPH, Robert Brown, MD (RAD)

Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center, Los Angeles, CA: Richard Casaburi, MD (PI), Janos Porszasz, MD, PhD, Hans Fischer, MD, PhD (RAD), Matt Budoff, MD

Michael E. DeBakey VAMC, Houston, TX: Amir Sharafkhaneh, MD (PI)

Minneapolis VA: Dennis Niewoehner, MD (PI), Tadashi Allen, MD (RAD), Kathryn Rice, MD

Morehouse School of Medicine, Atlanta, GA: Marilyn Foreman, MD, MS (PI), Gloria Westney, MD, MS, Eugene Berkowitz, MD, PhD

National Jewish Health, Denver, CO: Russell Bowler, MD, PhD (PI), Adam Friedlander, MD, Eleonora Meoni, MD

Temple University, Philadelphia, PA: Gerard Criner, MD (PI), Victor Kim, MD, Nathaniel Marchetti, DO, Aditi Satti, MD, A. James Mamary, MD, Robert Steiner, MD (RAD), Chandra Dass, MD (RAD)

University of Alabama, Birmingham, AL: William Bailey, MD (PI), Mark Dransfield, MD (Co-PI), Lynn Gerald, PhD, MSPH, Hrudaya Nath, MD (RAD)

University of California, San Diego, CA: Joe Ramsdell, MD (PI), Paul Ferguson, MS, RCP, Paul Friedman, MD (RAD)

University of Iowa, Iowa City, IA: Geoffrey McLennan, MD, PhD (PI), Edwin JR van Beek, MD, PhD (RAD)

University of Michigan, Ann Arbor, MI: Fernando Martinez, MD (PI), MeiLan Han, MD, Deborah Thompson, PhD, Ella Kazerooni, MD (RAD)

University of Minnesota, Minneapolis, MN: Christine Wendt, MD (PI), Tadashi Allen, MD (RAD)

University of Pittsburgh, Pittsburgh, PA: Frank Sciurba, MD (PI), Joel Weissfeld, MD, MPH, Carl Fuhrman, MD (RAD), Jessica Bon, MD

University of Texas Health Science Center at San Antonio, San Antonio, TX: Antonio Anzueto, MD (PI), Sandra Adams, MD, Carlos Orozco, MD, C. Santiago Restrepo, MD (RAD), Amy Mumbower, MD (RAD)

Administrative Core: James Crapo, MD (PI), Edwin Silverman, MD, PhD (PI), Barry Make, MD, Elizabeth Regan, MD, Jonathan Samet, MD, Amy Willis, MA, Douglas Stinson

Genetic Analysis Core: Terri Beaty, PhD, Barbara Klanderman, PhD, Nan Laird, PhD, Christoph Lange, PhD, Iuliana Ionita, Stephanie Santorico, PhD, Edwin Silverman, MD, PhD

Imaging Core: David Lynch, MD, Joyce Schroeder, MD, John Newell, Jr., MD, John Reilly, MD, Harvey Coxson, PhD, Philip Judy, PhD, Eric Hoffman, PhD, Raul San Jose Estepar, PhD, George Washko, MD, Rebecca Leek, Jordan Zach, Alex Kluiber, Anastasia Rodionova, Tanya Mann

PFT QA Core: Robert Crapo, MD, Robert Jensen, PhD

Biological Repository, Johns Hopkins University, Baltimore, MD: Homayoon Farzadegan, PhD

Data Coordinating Center and Biostatistics, National Jewish Health, Denver, CO: James Murphy, PhD, Douglas Everett, PhD, Carla Wilson

Epidemiology Core, University of Colorado School of Public Health, Denver, CO: John Hokanson, MPH, PhD,


Dr Regan has no conflicts to disclose, Dr Hokanson has no conflicts to disclose, Dr Murphy has no conflicts to disclose, Dr Make has no conflicts to disclose, Dr Lynch has received consulting fees from Intermune, Gilead, Centocor, and Novartis; he is a member of the advisory board for the BUILD-3 study sponsored by Actelion. Dr Beaty has no conflicts to disclose. Dr Curran-Everett has no conflicts to disclose. Dr Silverman has received grant funding from Glaxo Smith Kline, consulting fees from Astra Zeneca and Glaxo Smith Kline and honoraria from Bayer, Glaxo Smith Kline and Astra Zeneca, Dr Crapo has no conflicts to disclose.

Reference List

1. Hoyert DL, Arias E, Smith BL, et al. Deaths: final data for 1999. Natl Vital Stat Rep. 2001;49(8):1–113. [PubMed]
2. Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance--United States, 1971–2000. MMWR Surveill Summ. 2002;51(6):1–16. [PubMed]
3. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370(9589):765–73. [PubMed]
4. Friedlander AL, Lynch D, Dyar LA, et al. Phenotypes of chronic obstructive pulmonary disease. COPD. 2007;4(4):355–84. [PubMed]
5. Silverman EK. Exacerbations in chronic obstructive pulmonary disease: do they contribute to disease progression? Proc Am Thorac Soc. 2007;4(8):586–90. [PMC free article] [PubMed]
6. Lokke A, Lange P, Scharling H, et al. Developing COPD: a 25 year follow up study of the general population. Thorax. 2006;61(11):935–9. [PMC free article] [PubMed]
7. Kueppers F, Miller RD, Gordon H, et al. Familial prevalence of chronic obstructive pulmonary disease in a matched pair study. Am J Med. 1977;63(3):336–42. [PubMed]
8. Cohen BH, Ball WC, Jr, Brashears S, et al. Risk factors in chronic obstructive pulmonary disease (COPD) Am J Epidemiol. 1977;105(3):223–32. [PubMed]
9. McCloskey SC, Patel BD, Hinchliffe SJ, et al. Siblings of patients with severe chronic obstructive pulmonary disease have a significant risk of airflow obstruction. Am J Respir Crit Care Med. 2001;164(8 Pt 1):1419–24. [PubMed]
10. Silverman EK, Chapman HA, Drazen JM, et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med. 1998;157(6 Pt 1):1770–8. [PubMed]
11. Hersh CP, DeMeo DL, Reilly JJ, et al. Xenobiotic metabolizing enzyme gene polymorphisms predict response to lung volume reduction surgery. Respir Res. 2007;8:59. [PMC free article] [PubMed]
12. DeMeo DL, Hersh CP, Hoffman EA, et al. Genetic determinants of emphysema distribution in the national emphysema treatment trial. Am J Respir Crit Care Med. 2007;176(1):42–8. [PMC free article] [PubMed]
13. Hersh CP, Demeo DL, Lazarus R, et al. Genetic association analysis of functional impairment in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173(9):977–84. [PMC free article] [PubMed]
14. Gottlieb DJ, Wilk JB, Harmon M, et al. Heritability of longitudinal change in lung function. The Framingham study. Am J Respir Crit Care Med. 2001;164(9):1655–9. [PubMed]
15. Hoffman EA, Simon BA, McLennan G. State of the Art. A structural and functional assessment of the lung via multidetector-row computed tomography: phenotyping chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3(6):519–32. [PMC free article] [PubMed]
16. Van Steen K, McQueen MB, Herbert A, et al. Genomic screening and replication using the same data set in family-based association testing. Nat Genet. 2005;37(7):683–91. [PubMed]
17. Pillai SG, Ge D, Zhu G, et al. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet. 2009;5(3):e1000421. [PMC free article] [PubMed]
18. Wilk JB, Chen TH, Gottlieb DJ, et al. A genome-wide association study of pulmonary function measures in the Framingham Heart Study. PLoS Genet. 2009;5(3):e1000429. [PMC free article] [PubMed]
PubReader format: click here to try


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...